Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 183

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

Open access
Boss, D S, Glen, H, Beijnen, J H, Keesen, M, Morrison, R, Tait, B, Copalu, W, Mazur, A, Wanders, J, O'Brien, J P, Schellens, J H M, Evans, T R J·2012·British Journal of Cancer

Abstract

BACKGROUND: The objectives of this phase I study were to assess the safety and tolerability of E7080 in patients with advanced, refractory solid tumours; to determine the maximum tolerated dose (MTD) and pharmacokinetics profile of E7080; and to explore preliminary evidence of its anti-tumour efficacy. METHODS: E7080 was administered orally in escalating doses on a once-daily continuous schedule in 28-day cycles to eligible patients. Samples for pharmacokinetic analyses were collected on days 1, 8, 15 and 22 of cycle 1 and day 1 of cycle 2. Anti-tumour efficacy was assessed every two cycles. RESULTS: Eighty-two patients received E7080 in dose cohorts from 0.2 to 32 mg. Dose-limiting toxicities were grade 3 proteinuria (two patients) at 32 mg, and the MTD was defined as 25 mg. The most frequently observed cumulative toxicities (all grades) were hypertension (40% of patients), diarrhoea (45%), nausea (37%), stomatitis (32%) and vomiting (23%). Seven patients (9%) had a partial response and 38 patients (46%) had stable disease as best response. E7080 has dose-linear kinetics with no drug accumulation after 4 weeks' administration. CONCLUSION: E7080 is well tolerated at doses up to 25 mg per day. Encouraging anti-tumour efficacy was observed in patients with melanoma and renal cell carcinoma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bjc.2012.154

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 183

Metadata

Authors
Boss, D. S., Glen, H., Beijnen, J. H., Keesen, M., Morrison, R., Tait, B., Copalu, W., Mazur, A., Wanders, J., O'Brien, J. P., Schellens, J. H. M., & Evans, T. R. J.
Venue
British Journal of Cancer
Published
2012-04-19
Volume
106
Issue
10
Pages
1598-1604
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2095370944
Cited by
183
References
3
FWCI
9.56
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. https://app.cochat.ai/papers/10.1038/bjc.2012.154
The paper
Boss, D. S., Glen, H., Beijnen, J. H., Keesen, M., Morrison, R., Tait, B., Copalu, W., Mazur, A., Wanders, J., O'Brien, J. P., Schellens, J. H. M., & Evans, T. R. J. (2012). A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. British Journal of Cancer. https://doi.org/10.1038/bjc.2012.154

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.